Teva points to long-term efficacy of Ajovy in migraine

25 June 2025

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine.

The final data was presented at the Congress of the European Academy of Neurology congress in Helsinki, Finland, confirming that primary and secondary endpoints had been met.

Investigators concluded that the findings underscore the sustained effectiveness and the robust injection adherence rates to long-term Ajovy treatment in migraine prevention.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK